-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Fentanyl in Cancer Pain
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Fentanyl in Cancer PainDrug Details:Fentanyl (Wafernyl) is under development for the treatment of breakthrough cancer pain....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RMC-4630 in Breast Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RMC-4630 in Breast Cancer Drug Details: RMC-4630 is under development for the treatment of relapsed/refractory...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RMC-4630 in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RMC-4630 in Ovarian Cancer Drug Details: RMC-4630 is under development for the treatment of relapsed/refractory...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RMC-4630 in Prostate Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RMC-4630 in Prostate Cancer Drug Details: RMC-4630 is under development for the treatment of relapsed/refractory...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RMC-4630 in Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RMC-4630 in Colorectal Cancer Drug Details: RMC-4630 is under development for the treatment of relapsed/refractory...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RMC-4630 in Cervical Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RMC-4630 in Cervical Cancer Drug Details: RMC-4630 is under development for the treatment of relapsed/refractory...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RMC-4630 in Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RMC-4630 in Melanoma Drug Details: RMC-4630 is under development for the treatment of relapsed/refractory solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RMC-4630 in Colon Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RMC-4630 in Colon Cancer Drug Details: RMC-4630 is under development for the treatment of relapsed/refractory...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RMC-4630 in Liver Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RMC-4630 in Liver Cancer Drug Details: RMC-4630 is under development for the treatment of relapsed/refractory...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RMC-4630 in Lip Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RMC-4630 in Lip Cancer Drug Details: RMC-4630 is under development for the treatment of relapsed/refractory...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.